Welcome to the 7th RAS-Targeted Drug Development Summit
As recent advances in next-generation modalities to target mutant RAS progress from the bench to the clinic, the 7th RAS-Targeted Drug Development Summit returned with a refreshed and comprehensive program featuring strategies to overcome resistance, leverage combination therapies and improve patient stratification strategies for optimizing RAS-targeted drug durability.
You could join over 100 industry experts across 3 comprehensive days with deep-dive interactive sessions and data-driven presentations to accelerate RAS-targeting drugs to the patients in need.
Unmissable Agenda Highlights Included
Discover
Discover the latest modalities beyond covalent inhibitors paving the way for best-in-class, boasting improved durability of response, with talks on novel RAS-targeting degraders, molecular glues, cell therapies, vaccines and more with insights from Aethon Therapeutics, HB Therapeutics & Anocca
Deep-Dive
Deep dive into a variety of combination strategies for overcoming resistance, enhancing effectiveness, and prolonging treatment success for patients battling RAS-driven cancers with insights from Amgen, Bristol Myers Squibb & Verastem Oncology
Optimize
Optimize RAS-targeted drug efficacy by leveraging pan-(K)RAS inhibitors for deep and durable responses to treat PDAC, NSCLC and beyond with insights from Revolution Medicine & Abbisko Therapeutics
Attending Companies Included
Explore the Agenda
Hear the latest industry breakthroughs, cutting edge strategies as well as overcome RAS drug bottlenecks during our packed agenda consisting of deep dive workshops, interactive roundtables and data-driven case studies.
Partner With Us
Position yourself alongside other leading solution providers to ensure your brand is at the heart of RAS biopharma deals.
Join RAS Experts
Be part of the hottest conversations with like-minded attendees spanning all stages of drug development and make critical connections during our dedicated networking sessions.